Results 51 to 60 of about 1,948,666 (273)

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones [PDF]

Diabetes & Metabolism Journal, 2011
BackgroundSulfonylurea primarily stimulates insulin secretion by binding to its receptor on the pancreatic β-cells. Recent studies have suggested that sulfonylureas induce insulin sensitivity through peroxisome proliferator-activated receptor γ (PPARγ ...
Kyeong Won Lee, Yun Hyi Ku, Min Kim, Byung Yong Ahn, Sung Soo Chung, Kyong Soo Park   +5 more
doaj   +1 more source

Sulfonylurea derivatives of tolbutamide analogues: Synthesis and evaluation of antimicrobial and antioxidant activities [PDF]

, 2018
127-135A series of new sulfonylurea derivatives of tolbutamide analogues have been synthesized in a simple and effective way in high yields to explore the possibilities of some altered biological actions such as antibacterial, antifungal and antioxidant ...
Chalapathi, Ponne Venkata, Vijaya, Tartti, Babu, Pulluru Hari, Rasheed, S, Venkateswarlu, Nagam, Ramudu, D B Janaki, Raju, Chamarthi Naga   +6 more
core  

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

In Silico Study of New Sulfonylurea Analogs as Potential Antidiabetic Agents: ADMET, Molecular Docking and Dynamics, MM-GBSA and DFT Approach

Journal of Chemistry
Type 2 diabetes mellitus (T2DM) remains one of the leading causes of death globally. Current treatments of this disease involve using sulfonylurea, which is associated with cardiovascular risk and insulin resistance, among others.
Vhushavhelo Musinyali, Kabelo P. Mokgopa, Simon S. Mnyakeni-Moleele, Tendamudzimu Tshiwawa, Ndivhuwo R. Tshiluka   +4 more
doaj   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

Comparative assessment of kidney function biomarkers related to anti-diabetic medication consumption; a cross-sectional analysis [PDF]

Journal of Nephropathology
Introduction: Diabetic nephropathy is a main cause of chronic kidney disease (CKD) throughout the world, which requiring early detection and management.
Qutaiba A. Qasim, Hiba Dawood
doaj   +1 more source

Weight change and risk of cardiovascular disease among adults with type 2 diabetes: more than 14 years of follow-up in the Tehran Lipid and Glucose Study

Cardiovascular Diabetology, 2021
Background To examine the impact of weight change on incident cardiovascular disease and coronary heart disease (CVD/CHD) among an Iranian population with type 2 diabetes mellitus (T2DM).
Seyyed Saeed Moazzeni, Reyhane Hizomi Arani, Niloofar Deravi, Mitra Hasheminia, Davood Khalili, Fereidoun Azizi, Farzad Hadaegh   +6 more
doaj   +1 more source

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin [PDF]

Diabetes & Metabolism Journal, 2015
BackgroundDipeptidyl peptidase-4 (DPP-4) inhibitor add-on therapy is a new option for patients with inadequately controlled type 2 diabetes who are taking combined metformin and sulfonylurea (SU).
Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi   +9 more
doaj   +1 more source